Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs FirstEnergy Corp. (FE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs FirstEnergy Corp. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while FirstEnergy Corp. trades at $47.92 (market cap $27.72B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and FirstEnergy Corp. pays a 3.88% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FE | |
|---|---|---|
Market Cap | $39.89B | $27.72B |
Sector | Health | Utilities |
52-Week High | $491.22 | $51.91 |
52-Week Low | $278.09 | $40.30 |
Enterprise Value | $38.15B | $55.73B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FirstEnergy (FE) trades at $47.92, up 0.61% with neutral technical signals. The company shows steady revenue growth to $15.09B in 2025 and a net income margin of 6.86%, though cash flow remains negative. Recent news highlights opportunities from surging data center demand and a $36B investment plan for grid upgrades. Analyst consensus is mixed with a $52 price target, indicating potential upside from current levels.
Outlook is cautiously optimistic given FE's strategic investments and data center tailwinds, but risks include regulatory uncertainty and high debt levels. The stock presents a balanced opportunity for investors seeking utility exposure with growth potential, though monitoring earnings execution and capex efficiency is crucial for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
